echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > IDH wild-type diffuse glioma versus typical glioblastoma

    IDH wild-type diffuse glioma versus typical glioblastoma

    • Last Update: 2022-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hayato Suzuki et al.



    ——Excerpt from the article chapter

    【Ref: Suzuki H, et al.



    Research background

    Diffuse gliomas account for about 80% of primary malignant brain tumors in adults, classified as isocitrate dehydrogenase (IDH) wild type (IDHwt) or mutant type (IDHmut); The former is currently thought to be glioblastoma (GBM



    There is currently no definite definition



    The researchers extracted patient data from hospital databases, including age, sex, scope of resection, radiotherapy and chemotherapy regimens, and overall survival




    Results of the study

    The results of the NGS and MGMT promoter methylation assessment showed that the frequency of PI3K/MAPK pathway gene mutations was high (8 cases, 88.



    The results of the survival analysis showed that the median follow-up period for this group of cases was 26.




    The study investigated the clinical, histological and molecular features of IDHwt diffuse gliomas, and the results showed that IDHwt diffuse gliomas consisted mainly of low-grade gliomas, and that PI3K/MAPK pathway gene variants were found in most cases, but no other molecular features of GBM were found, which may not have progressed to GBM, which explains why the prognosis of this group of cases is better
    than that of the reference sequence.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.